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Questions : EASL interview 
1.  What is different in the 2018 update compared to the previous publication in 2012? 
2.  How do you advise a clinician to use the NAFLD guideline in clinical practice? 
3. Significant efforts in diagnostics and therapeutics are occurring in NAFLD. Do you see 
this as having an impact on the frequency guideline updates?.  When do you see a 
dynamic platform (such as that used for the HCV guidance document) as being 
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EIC Blurb: 
In February 2018 AASLD published an update to the practice guideline on the prevention, 
diagnosis, and treatment of chronic hepatitis B (CHB). [LINK] In contrast the prior version. 
this guidance 
 
document was developed by consensus of an expert panel, without formal 
systematic review or use of the Grading of Recommendations Assessment, 
Development, and Evaluation system. The 2018 guidance is based upon the following: 
(1) formal review and analysis of published literature on the topics; (2) World Health 
Organization guidance on prevention, care, and treatment of CHB; and (3) the authors’ 
experience in acute hepatitis B and CHB. This guidance is intended for use by health care 
providers, this guidance identifies preferred approaches to the diagnostic, therapeutic, and 
preventive aspects of care for patients with CHB. As with clinical practice guidelines, it provides 
general guidance to optimize the care of the majority of patients and should not replace clinical 
judgement for a unique patient. This guidance does not seek to dictate a “one size fits all” approach 
for the management of CHB. Clinical considerations may justify a course of action that differs from 
this guidance. 
 
The 2018 HBV guideline is intended to complement the previous editions.  The update addresses 
five major areas of change.  The new version (1) includes updates on treatment since the 2016 HBV 
guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, 
and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated 
patients; and (5) treatment of hepatitis B in special populations, including persons with viral 
coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients. 
 
Please listen to Dr Norah Terrault discuss  [Modify after interview]  
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